SCHEMBL2394432

SCHEMBL2394432

O=C(O)Cc1ccc(Cl)cc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
AKR1B1 P15121 1/20 0.52
CXCL8 P10145 1/20 0.49
CYP2C9 P11712 1/20 0.49
CHRM1 P11229 1/20 0.49
POLB P06746 2/20 0.49
CA2 P00918 2/20 0.48
CA1 P00915 1/20 0.48
MAPT P10636 3/20 0.47
CYP3A4 P08684 2/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 2/20 0.47
BLM P54132 2/20 0.47
HIF1A Q16665 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SLC22A1 O15245 1/20 0.47
USP2 O75604 1/20 0.47
HSP90AA1 P07900 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3141863 0.86 HIF1A (0.61) KEAP1NFE2L2AKR1B1CXCL8CYP2C9
SCHEMBL16041940 0.85 KEAP1 (0.54) KEAP1NFE2L2AKR1B1CXCL8CYP2C9
SCHEMBL6184686 0.84 SIRT1 (0.46) POLBCA2CA1MAPTCYP3A4
SCHEMBL25852925 0.84 MEN1 (0.44) KEAP1NFE2L2AKR1B1CYP2C9POLB
SCHEMBL348979 0.84 KEAP1 (0.50) KEAP1NFE2L2AKR1B1CXCL8CYP2C9
SCHEMBL29434734 0.84 KEAP1 (0.50) KEAP1NFE2L2AKR1B1CXCL8CYP2C9
SCHEMBL260512 0.83 CHRM1 (0.57) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL29419329 0.83 CHRM1 (0.57) KEAP1NFE2L2CXCL8CYP2C9CHRM1
SCHEMBL31155820 0.82 POLB (0.58) POLBCA2CA1ALOX15
SCHEMBL2392851 0.82 POLB (0.58) POLBCA2CA1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092029-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE SCRIPPS RESEARCH INST (US) 2026-04-02 US claimed
EP-4584236-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE The Scripps Research Institute (US) 2025-07-16 EP claimed
WO-2024054881-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-03-14 WO claimed
US-20260092029-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE SCRIPPS RESEARCH INST (US) 2026-04-02 US disclosed
EP-4584236-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE The Scripps Research Institute (US) 2025-07-16 EP disclosed
WO-2024054881-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-03-14 WO disclosed
WO-2017046255-A1 MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS Janssen Pharmaceuticals, Inc. (US) 2017-03-23 WO disclosed
EP-1765768-B1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2013-11-06 EP disclosed
US-8022248-B2 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid ASTRAZENECA AB (SE) 2011-09-20 US disclosed
US-20100081692-A1 Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma ASTRAZENECA AB (SE) 2010-04-01 US disclosed
EP-1945613-A1 NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA AstraZeneca AB (SE) 2008-07-23 EP disclosed
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US disclosed
WO-2007053082-A1 NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA ASTRAZENECA AB (SE) 2007-05-10 WO disclosed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO disclosed
EP-1037880-A1 RETINOIC ACID MIMETIC ANILIDES JANSSEN PHARMACEUTICA N.V. (BE) 2000-09-27 EP disclosed
WO-1999029674-A1 RETINOIC ACID MIMETIC ANILIDES JANSSEN PHARMACEUTICA N.V. (BE) 1999-06-17 WO disclosed
US-5395964-A Preparation process for hydroxyphenylacetic acids SOCIETE FRANCAISE HOECHST (FR) 1995-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092029-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE CYP2B6, CYP2A6, CYP1A1 KEAP1 479/4885NFE2L2 377/4885AKR1B1 363/4885
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases HRH2, HRH1, HRH4 KEAP1 1340/4885NFE2L2 1835/4885AKR1B1 287/4885
US-20100081692-A1 Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma CCR1, CCR4, CCR10 KEAP1 152/4885NFE2L2 794/4885AKR1B1 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.